Stay updated with breaking news from Sofie Qiao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,...
/PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,...
/PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,...
Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing. The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace. The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activat...
Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway News provided by Share this article Share this article SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. The Series C financing w...